A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 407-413

  Koizumi, Wasaburo ^a   Nakayama, Norisuke ^b   Tanabe, Satoshi ^a   Sasaki, Tohru ^a   Higuchi, Katsuhiko ^a   Nishimura, Ken ^b   Takagi, Seiichi ^b   Azuma, Mizutomo ^a   Ae, Takako ^a   Ishido, Kenji ^a   Nakatani, Kento ^c   Naruke, Akira ^a   Katada, Chikatoshi ^c  

^a KITASATO UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cisplatin; Docetaxel; Gastric cancer; Phase II; S 1 (combination)

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN C;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; OXONIC ACID; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 84856720941     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1701-1     Document Type: Article

References (14)

1. F Kamangar GM Dores WF Anderson 2006 Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 14 2137 2150 16682732 10.1200/JCO.2005.05.2308 (Pubitemid 46655601)
2. N Munoz S Franceschi 1997 Epidemiology of gastric cancer and perspectives for prevention Salud Publica Mex 39 4 318 330 9337564 1:STN:280: DyaK2svnvVyisA%3D%3D (Pubitemid 27408776)
3. Ministry of Health Law. Vital Statistics of Japan (2009)
4. T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura, et al. 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 5 548 557 8862723 10.1097/00001813-199607000-00010 1:CAS:528:DyaK28Xltleru78%3D (Pubitemid 26276346)
5. N Boku S Yamamoto H Fukuda K Shirao T Doi A Sawaki, et al. 2009 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 11 1063 1069 19818685 10.1016/S1470-2045(09)70259-1 1:CAS:528:DC%2BD1MXhtlGit7bI
6. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi, et al. 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 3 215 221 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D
7. JA Ajani W Rodriguez G Bodoky V Moiseyenko M Lichinitser V Gorbunova, et al. 2010 Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 9 1547 1553 20159816 10.1200/JCO.2009.25.4706 1:CAS:528:DC%2BC3cXltFGhtr0%3D
8. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni, et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 31 4991 4997 17075117 10.1200/JCO.2006.06.8429 (Pubitemid 46631401)
9. N Nakayama W Koizumi T Sasaki K Higuchi S Tanabe K Nishimura, et al. 2008 A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601) Oncology 75 1-2 1 7 18719348 10.1159/000151613 1:CAS:528:DC%2BD1cXhtFKgsrjO
10. K Yoshida M Ninomiya N Takakura N Hirabayashi W Takiyama Y Sato, et al. 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 3407 16740764 10.1158/1078-0432.CCR-05-2425 1:CAS:528:DC%2BD28XltFyis7k%3D
11. K Yamaguchi T Shimamura I Hyodo W Koizumi T Doi H Narahara, et al. 2006 Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer Br J Cancer 94 12 1803 1808 16773074 10.1038/sj.bjc.6603196 1:CAS:528: DC%2BD28XlsFequ7Y%3D (Pubitemid 43884569)
12. M Fujii 2008 Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study) Int J Clin Oncol 13 3 201 205 18553228 10.1007/s10147-008-0775-1 1:CAS:528:DC%2BD1cXntFKhsrY%3D (Pubitemid 351871896)
13. Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S et al (2010) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66:721-728
14. WB Al-Refaie JF Tseng G Gay L Patel-Parekh PF Mansfield PWT Pisters JC Yao BW Feig 2008 The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma Cancer 113 461 469 18553367 10.1002/cncr.23572